Citizens Reiterates Buy Rating for Intellia Therapeutics
Citizens maintains a bullish outlook on Intellia Therapeutics with a $30 target, a 91.45% upside from the current price.
Key Points
- On June 15, 2026, Citizens reiterated its buy rating for Intellia Therapeutics, setting a $30 price target.
- Citizens's $30 price target implies 91.45% upside from Intellia Therapeutics, Inc.'s ($NTLA) current $15.67 share price.
- Intellia Therapeutics trades at $12.11, with a market cap of approximately $1.69 billion and a 52-week high of $28.25.
- Insider purchases were reported on June 9, 2026, with several insiders acquiring shares without a disclosed price.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 15, 2026, Citizens reiterated its buy rating for Intellia Therapeutics, Inc. (NasdaqGM: NTLA), maintaining a price target of $30. This decision comes as the stock trades at around $12.11.
Other Institutional Activity in Intellia Therapeutics
ARK Investment Management LLC increased its holdings by 301,923 shares, ending with 14,509,247 shares valued at about $186 million. BlackRock, Inc. boosted its position by 1,878,957 shares, now holding 12,155,806 shares worth roughly $155.8 million. State Street Corp added 503,840 shares, bringing its total to 6,922,676 shares valued at approximately $88.7 million. D. E. Shaw & Co., Inc. also increased its stake by 397,113 shares, totaling 5,728,177 shares with a value of $73.4 million.
Intellia Therapeutics, Inc. Stock Up 21.8%
Shares of NasdaqGM:NTLA are trading near $12.11. Intellia Therapeutics has a market cap of about $1.69 billion. The stock has a 52-week low of $7.95 and a high of $28.25. It has a 50-day moving average of $13.63 and a 200-day moving average of $13.39. The company shows a forward P/E ratio that is not meaningful because it is not profitable, with a beta of 1.815.
Recent Earnings
Intellia Therapeutics reported revenue of $66.1 million, reflecting a decline of 9.5%. The company has a net margin of 0% and a return on equity of -56.34%. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Intellia Therapeutics, Inc.
On June 9, 2026, several insiders, including Fred Cohen, William Chase, and Brian Goff, each acquired 13,300 shares. Muna Bhanji and Georgia Keresty also purchased 9,200 and 13,300 shares, respectively. These transactions were not part of planned sales.
Analysts Set New Price Targets
On June 15, 2026, Citizens reiterated a buy rating with a $30 price target. Wedbush also reiterated its hold rating with a $12 target on the same day. Earlier, Bernstein maintained a hold rating with a $17 target on May 13, 2026. The consensus among 19 analysts is a buy recommendation, with an average price target of $26.63.
About Intellia Therapeutics
Intellia Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts. It focuses on developing therapies using CRISPR/Cas9 technology for genome editing. The company is working on treatments for conditions like transthyretin amyloidosis and hereditary angioedema. Intellia collaborates with various partners to advance its therapeutic pipeline.
Bottom Line
Citizens' reiterated buy rating underscores continued interest in Intellia Therapeutics' potential in genome editing technologies. With its current stock price and analyst targets, investors are closely watching its development efforts. As a reminder, analyst ratings are forward-looking and can change as new information becomes available.
Get Intellia Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $NTLA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.